000			01900 a2200601 4500
005			20250517132720.0
264		0	_c20170228
008			201702s 0 0 eng d
022			_a1665-2681
024	7		_a10.5604/16652681.1226817 _2doi
040			_aNLM _beng _cNLM
100	1		_aKöklü, Seyfettin
245	0	0	_a Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program. _h[electronic resource]
260			_bAnnals of hepatology _c
300			_a71-76 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAged
650	0	4	_aAntiviral Agents _xadverse effects
650	0	4	_aCarbamates
650	0	4	_aCost-Benefit Analysis
650	0	4	_aDrug Costs
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aGenotype
650	0	4	_aHealth Services Accessibility _xeconomics
650	0	4	_aHepacivirus _xdrug effects
650	0	4	_aHepatitis C, Chronic _xdiagnosis
650	0	4	_aHumans
650	0	4	_aImidazoles _xadverse effects
650	0	4	_aIsoquinolines _xadverse effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProgram Evaluation
650	0	4	_aPyrrolidines
650	0	4	_aRNA, Viral _xgenetics
650	0	4	_aSulfonamides _xadverse effects
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
650	0	4	_aTurkey
650	0	4	_aValine _xanalogs & derivatives
650	0	4	_aViral Load
700	1		_aKöksal, Iftihar
700	1		_aAkarca, Ulus Salih
700	1		_aBalkan, Ayhan
700	1		_aGüner, Rahmet
700	1		_aDemirezen, Aylin
700	1		_aSahin, Memduh
700	1		_aAkhan, Sila
700	1		_aOzaras, Reşat
700	1		_aIdilman, Ramazan
773	0		_tAnnals of hepatology _gvol. 16 _gno. 1 _gp. 71-76
856	4	0	_uhttps://doi.org/10.5604/16652681.1226817 _zAvailable from publisher's website
999			_c26751887 _d26751887